“…Except for a small number of epidemiological surveys describing SCRA use (Barratt, Cakic, & Lenton, 2013; Castellanos, Singh, Thornton, Avila, & Moreno, 2011; Caviness, Tzilos, Anderson, & Stein, 2015; Hu, Primack, Barnett, & Cook, 2011; Johnson, Johnson, & Portier, 2013; Vandrey, Dunn, Fry, & Girling, 2012; Winstock & Barratt, 2013a, 2013b), most of this literature informs either the neuropharmacology and neurophysiology of these products (Grigoryev, et al, 2011; Kavanagh, Grigoryev, Savchuk, Mikhura, & Formanovsky, 2013) or the adverse effects observed on emergency department patients (Besli, Ikiz, Yildirim, & Saltik, 2015; Bonar, Ashrafioun, & Ilgen, 2014; Johnson, et al, 2013; Tait, Caldicott, Mountain, Hill, & Lenton, 2016). Collecting information regarding SCRA patterns of use and related effects remains challenging because SCRA users are sometimes difficult to reach through conventional epidemiological surveillance methods.…”